Justempa 25 Tablet contains Empagliflozin 25 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is indicated for the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents, to improve glycemic control. Empagliflozin works by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering blood glucose levels. In addition to glycemic benefits, Empagliflozin has demonstrated cardiovascular and renal protective effects in patients with type 2 diabetes at high risk of cardiovascular events. Justempa 25 Tablet should be administered once daily, with or without food, as prescribed by a healthcare professional. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to the active substance. Common adverse effects may include urinary tract infections, genital mycotic infections, increased urination, and dehydration. Patients should be monitored for signs of volume depletion and renal function periodically. Proper patient education regarding hydration and recognition of symptoms is essential to optimize therapy and minimize risks. Justempa 25 Tablet offers an effective option for improving glycemic control and reducing cardiovascular risk in type 2 diabetes management.